체외진단용 실험실 자동화 시장 예측(-2030년) : 제품별, 장비별, 기술별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Lab Automation for In-Vitro Diagnostic Market is accounted for $131.59 billion in 2024 and is expected to reach $193.09 billion by 2030 growing at a CAGR of 6.60% during the forecast period. Medical laboratory operations are completely transformed by lab automation for in-vitro diagnostics, which increases productivity by optimizing workflows. Tasks like sample preparation, analysis, and data management are automated, lowering human error and boosting throughput by combining sophisticated robotics, software, and instrumentation. With the help of this technology, patients can receive a diagnosis and make treatment decisions more quickly thanks to rapid and accurate testing.

According to the American Association for Clinical Chemistry (AACC), laboratory automation plays a crucial role in modern healthcare by improving efficiency, reducing errors, and ultimately enhancing patient care outcomes.

Market Dynamics:

Driver:

Growing requirement for high-throughput evaluation

Clinical diagnostics, genomics, drug discovery, and other fields are finding increasing applications for high-throughput screening (HTS) techniques. With HTS, a large compound library can be quickly screened to find possible drug candidates in the drug discovery process. Moreover, the analysis of massive genomic data for uses like cancer genomics and personalized medicine is similarly made easier in the field of genomics by HTS technologies like next-generation sequencing (NGS).

Restraint:

Excessive initial capital outlay

Lab automation system implementation necessitates a large upfront investment in personnel training, software, hardware, and infrastructure. For laboratories, especially smaller ones with tighter budgets, the high cost of automation platforms such as robotic systems, liquid handling workstations, and integrated laboratory information management systems (LIMS) can be a financial burden. Furthermore, the total cost of ownership is further increased by continuing costs for software updates, calibration, and maintenance, which may discourage adoption among budget-conscious businesses.

Opportunity:

Point-of-care testing (POCT) expansion

Point-of-care testing (POCT) is becoming more widely used in a variety of healthcare settings, such as clinics, pharmacies, hospitals, and community-based facilities. This is due to the growing demand for decentralized testing solutions and quick diagnostic services. Moreover, by enabling on-site testing, real-time result delivery, and prompt clinical intervention, POCT devices, handheld analyzers, portable diagnostic instruments, and smart phone-based applications improve patient access to timely diagnosis and healthcare outcomes.

Threat:

Market Saturation and vigorous rivalry

A wide range of automation solutions and diagnostic assays are offered by a number of global players, specialized manufacturers, and start-ups in the fiercely competitive lab automation for in-vitro diagnostics market. Market saturation puts downward pressure on profit margins and revenue growth for industry incumbents, especially when combined with fierce price competition and the commoditization of automation platforms. Additionally, the rise of substitute products, disruptive technologies, and new competitors increases the pressure on existing ones, causing price wars, market share erosion, and market consolidation.

Covid-19 Impact:

The market for lab automation for in-vitro diagnostics has been significantly impacted by the COVID-19 pandemic, which has brought about both opportunities and challenges. Although the pandemic slowed market growth initially due to supply chain disruptions, manufacturing delays, and healthcare facilities temporarily closing, it also accelerated the adoption of automation technologies to meet the spike in demand for diagnostic testing. Furthermore, solutions for laboratory automation were essential in helping to support pandemic response efforts and enable the safe reopening of economies by increasing testing capacity, optimizing sample processing, and shortening turnaround times for COVID-19 testing.

The Reagents and Kits segment is expected to be the largest during the forecast period

Reagents and kits usually have the largest market share in the lab automation for in-vitro diagnostics market. These necessary elements include a broad range of materials, such as biochemical, antibodies, and probes that are utilized in diagnostic testing procedures. From simple blood analyses to intricate molecular diagnostics, reagents and kits are the cornerstone of many tests. Moreover, their ubiquity is attributed to their necessity in a variety of diagnostic applications as well as the ongoing need for precise and effective testing methods.

The Automated Liquid Handler segment is expected to have the highest CAGR during the forecast period

In the lab automation for in vitro diagnostic market, the automated liquid handler usually exhibits the highest CAGR. With the least amount of human involvement, automated liquid handlers simplify the process of precisely dispensing liquids-such as reagents and samples-into different containers, plates, or tubes. With the help of this technology, laboratory workflows can be made much more efficient, accurate, and productive. Additionally, the growing need for quicker and more standardized diagnostic processes, as well as the need to lower errors and enhance reproducibility in laboratory operations, are what are driving the increasing adoption of automated liquid handling systems.

Region with largest share:

The market for lab automation for in-vitro diagnostics is dominated by North America. The region's early adoption of cutting-edge technologies, substantial investment in research and development, and sophisticated healthcare infrastructure are all credited with its dominance. Leading market participants, supportive government policies, and financing for medical research all contribute to North America's dominant position in the industry. Furthermore, the need for effective and precise diagnostic solutions is fueled by the aging population and the high prevalence of chronic diseases.

Region with highest CAGR:

The lab automation for in-vitro diagnostic market is anticipated to grow at the highest CAGR in the Asia-Pacific region. Numerous factors, such as rising healthcare costs, growing healthcare infrastructure, and a growing emphasis on advanced diagnostic technologies, are responsible for this rapid growth. The need for effective and precise diagnostic tools is fueled by the aging population and the rising incidence of chronic diseases. Additionally, the area also gains from significant public and private healthcare investments, as well as from supportive government programs targeted at modernizing laboratory services.

Key players in the market

Some of the key players in Lab Automation For In-Vitro Diagnostic market include F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Cognex Corporation, Quidel Corporation, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Chembio Diagnostics, Inc, Bio-Rad Laboratories, Inc., Surmodics, Inc., Danaher Corporation, Tecan Group Ltd, Sysmex Corporation, Agilent Technologies Inc. and PerkinElmer Inc.

Key Developments:

In January 2024, BD (Becton, Dickinson and Company), a leading global medical technology company, announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In August 2023, Cognex Corporation, a leader in industrial machine vision, announced it has agreed to acquire Moritex Corporation (Moritex) from Trustar Capital, a private equity affiliate of CITIC Capital Holdings Limited, for ¥40 billion (approximately $275 million), in an all-cash transaction. Moritex is a leading global provider of optics components with a strong presence in Japan.

Products Covered:

• Reagents and Kits
• Instruments
• Data Management Software
• Other Products

Equipments Covered:

• Automated Plate Handler
• Automated Liquid Handler
• Robotic Arm
• Automated Storage and Retrieval System
• Analyzer
• Other Equipments

Technologies Covered:

• Immunoassay/ Immunochemistry
• Clinical Chemistry
• Hematology
• Molecular Diagnostics
• Microbiology
• Coagulation And Hemostasis
• Urinalysis
• Other Technologies

Applications Covered:

• Infectious Diseases
• Diabetes
• Drug Testing/ Pharmacogenomics
• Autoimmune Diseases
• Oncology
• Cardiology
• HIV/AIDS
• Nephrology
• Other Applications

End Users Covered:

• Hospital Laboratories
• Point-Of-Care Testing Centers
• Academic Institutes
• Clinical Laboratories
• Patients
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Lab Automation For In-Vitro Diagnostic Market, By Product

• 5.1 Introduction
• 5.2 Reagents and Kits
• 5.3 Instruments
• 5.4 Data Management Software
• 5.5 Other Products

6 Global Lab Automation For In-Vitro Diagnostic Market, By Equipment

• 6.1 Introduction
• 6.2 Automated Plate Handler
• 6.3 Automated Liquid Handler
• 6.4 Robotic Arm
• 6.5 Automated Storage and Retrieval System
• 6.6 Analyzer
• 6.7 Other Equipments

7 Global Lab Automation For In-Vitro Diagnostic Market, By Technology

• 7.1 Introduction
• 7.2 Immunoassay/ Immunochemistry
• 7.3 Clinical Chemistry
• 7.4 Hematology
• 7.5 Molecular Diagnostics
• 7.6 Microbiology
• 7.7 Coagulation And Hemostasis
• 7.8 Urinalysis
• 7.9 Other Technologies

8 Global Lab Automation For In-Vitro Diagnostic Market, By Application

• 8.1 Introduction
• 8.2 Infectious Diseases
• 8.3 Diabetes
• 8.4 Drug Testing/ Pharmacogenomics
• 8.5 Autoimmune Diseases
• 8.6 Oncology
• 8.7 Cardiology
• 8.8 HIV/AIDS
• 8.9 Nephrology
• 8.10 Other Applications

9 Global Lab Automation For In-Vitro Diagnostic Market, By End User

• 9.1 Introduction
• 9.2 Hospital Laboratories
• 9.3 Point-Of-Care Testing Centers
• 9.4 Academic Institutes
• 9.5 Clinical Laboratories
• 9.6 Patients
• 9.7 Other End Users

10 Global Lab Automation For In-Vitro Diagnostic Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 F. Hoffmann-La Roche Ltd
• 12.2 Becton, Dickinson and Company
• 12.3 Cognex Corporation
• 12.4 Quidel Corporation
• 12.5 Abbott Laboratories
• 12.6 Siemens Healthineers AG
• 12.7 Thermo Fisher Scientific Inc.
• 12.8 Chembio Diagnostics, Inc
• 12.9 Bio-Rad Laboratories, Inc.
• 12.10 Surmodics, Inc.
• 12.11 Danaher Corporation
• 12.12 Tecan Group Ltd
• 12.13 Sysmex Corporation
• 12.14 Agilent Technologies Inc.
• 12.15 PerkinElmer Inc.